Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Sabbagh v. Cell Therapeutics Inc et al
Case Number:
2:10-cv-00414
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Brower Piven
- Fox Rothschild
- Hagens Berman
- Kahn Swick
- Karr Tuttle
- Keller Rohrback
- Kessler Topaz
- Lieff Cabraser
- O'Melveny & Myers
- Robbins Geller
- Ropes & Gray
- Wilk Auslander
- Wilson Sonsini
Companies
Sectors & Industries:
-
February 14, 2012
Cell Therapeutics Settles Investor Lawsuit For $19M
Seattle-based biotechnology company Cell Therapeutics Inc. agreed to pay $19 million to settle a class action by investors who contended the company's stock price was artificially inflated due to misleading statements about a pipeline drug, according to a Tuesday court filing.
-
February 07, 2011
Cell Therapeutics Fails To Nix Investor Class Action
A federal judge has refused to dismiss a consolidated class action accusing biopharmaceutical company Cell Therapeutics Inc. and its executives of misleading investors into believing the U.S. Food and Drug Administration was poised to approve a new cancer treatment product.